Cargando…

A case of interstitial lung disease with alveolar hemorrhage induced by pembrolizumab

We herein describe the case of a 67-year-old woman with advanced lung adenocarcinoma who developed interstitial lung disease (ILD) with alveolar hemorrhage induced by pembrolizumab. She received four courses of pembrolizumab therapy and achieved a partial response. She had no respiratory symptoms; h...

Descripción completa

Detalles Bibliográficos
Autores principales: Sugano, Teppei, Seike, Masahiro, Noro, Rintaro, Kaburaki, Syota, Tozuka, Takehiro, Takahashi, Akihiko, Takano, Natsuki, Tanaka, Toru, Kashiwada, Takeru, Takeuchi, Susumu, Minegishi, Yuji, Saito, Yoshinobu, Kubota, Kaoru, Terasaki, Yasuhiro, Gemma, Akihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6149979/
https://www.ncbi.nlm.nih.gov/pubmed/30271171
http://dx.doi.org/10.2147/OTT.S169321
_version_ 1783356909740359680
author Sugano, Teppei
Seike, Masahiro
Noro, Rintaro
Kaburaki, Syota
Tozuka, Takehiro
Takahashi, Akihiko
Takano, Natsuki
Tanaka, Toru
Kashiwada, Takeru
Takeuchi, Susumu
Minegishi, Yuji
Saito, Yoshinobu
Kubota, Kaoru
Terasaki, Yasuhiro
Gemma, Akihiko
author_facet Sugano, Teppei
Seike, Masahiro
Noro, Rintaro
Kaburaki, Syota
Tozuka, Takehiro
Takahashi, Akihiko
Takano, Natsuki
Tanaka, Toru
Kashiwada, Takeru
Takeuchi, Susumu
Minegishi, Yuji
Saito, Yoshinobu
Kubota, Kaoru
Terasaki, Yasuhiro
Gemma, Akihiko
author_sort Sugano, Teppei
collection PubMed
description We herein describe the case of a 67-year-old woman with advanced lung adenocarcinoma who developed interstitial lung disease (ILD) with alveolar hemorrhage induced by pembrolizumab. She received four courses of pembrolizumab therapy and achieved a partial response. She had no respiratory symptoms; however, chest radiography and computed tomography (CT) revealed ground-glass opacities (GGOs) and crazy-paving pattern. Based on findings of bloody bronchoalveolar lavage fluid and transbronchial lung biopsy samples, pembrolizumab-induced ILD with alveolar hemorrhage was diagnosed. Corticosteroid therapy rapidly improved alveolar hemorrhage and regressed GGOs on CT scan. This is the first report on ILD with alveolar hemorrhage induced by pembrolizumab.
format Online
Article
Text
id pubmed-6149979
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-61499792018-09-28 A case of interstitial lung disease with alveolar hemorrhage induced by pembrolizumab Sugano, Teppei Seike, Masahiro Noro, Rintaro Kaburaki, Syota Tozuka, Takehiro Takahashi, Akihiko Takano, Natsuki Tanaka, Toru Kashiwada, Takeru Takeuchi, Susumu Minegishi, Yuji Saito, Yoshinobu Kubota, Kaoru Terasaki, Yasuhiro Gemma, Akihiko Onco Targets Ther Case Series We herein describe the case of a 67-year-old woman with advanced lung adenocarcinoma who developed interstitial lung disease (ILD) with alveolar hemorrhage induced by pembrolizumab. She received four courses of pembrolizumab therapy and achieved a partial response. She had no respiratory symptoms; however, chest radiography and computed tomography (CT) revealed ground-glass opacities (GGOs) and crazy-paving pattern. Based on findings of bloody bronchoalveolar lavage fluid and transbronchial lung biopsy samples, pembrolizumab-induced ILD with alveolar hemorrhage was diagnosed. Corticosteroid therapy rapidly improved alveolar hemorrhage and regressed GGOs on CT scan. This is the first report on ILD with alveolar hemorrhage induced by pembrolizumab. Dove Medical Press 2018-09-17 /pmc/articles/PMC6149979/ /pubmed/30271171 http://dx.doi.org/10.2147/OTT.S169321 Text en © 2018 Sugano et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Case Series
Sugano, Teppei
Seike, Masahiro
Noro, Rintaro
Kaburaki, Syota
Tozuka, Takehiro
Takahashi, Akihiko
Takano, Natsuki
Tanaka, Toru
Kashiwada, Takeru
Takeuchi, Susumu
Minegishi, Yuji
Saito, Yoshinobu
Kubota, Kaoru
Terasaki, Yasuhiro
Gemma, Akihiko
A case of interstitial lung disease with alveolar hemorrhage induced by pembrolizumab
title A case of interstitial lung disease with alveolar hemorrhage induced by pembrolizumab
title_full A case of interstitial lung disease with alveolar hemorrhage induced by pembrolizumab
title_fullStr A case of interstitial lung disease with alveolar hemorrhage induced by pembrolizumab
title_full_unstemmed A case of interstitial lung disease with alveolar hemorrhage induced by pembrolizumab
title_short A case of interstitial lung disease with alveolar hemorrhage induced by pembrolizumab
title_sort case of interstitial lung disease with alveolar hemorrhage induced by pembrolizumab
topic Case Series
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6149979/
https://www.ncbi.nlm.nih.gov/pubmed/30271171
http://dx.doi.org/10.2147/OTT.S169321
work_keys_str_mv AT suganoteppei acaseofinterstitiallungdiseasewithalveolarhemorrhageinducedbypembrolizumab
AT seikemasahiro acaseofinterstitiallungdiseasewithalveolarhemorrhageinducedbypembrolizumab
AT nororintaro acaseofinterstitiallungdiseasewithalveolarhemorrhageinducedbypembrolizumab
AT kaburakisyota acaseofinterstitiallungdiseasewithalveolarhemorrhageinducedbypembrolizumab
AT tozukatakehiro acaseofinterstitiallungdiseasewithalveolarhemorrhageinducedbypembrolizumab
AT takahashiakihiko acaseofinterstitiallungdiseasewithalveolarhemorrhageinducedbypembrolizumab
AT takanonatsuki acaseofinterstitiallungdiseasewithalveolarhemorrhageinducedbypembrolizumab
AT tanakatoru acaseofinterstitiallungdiseasewithalveolarhemorrhageinducedbypembrolizumab
AT kashiwadatakeru acaseofinterstitiallungdiseasewithalveolarhemorrhageinducedbypembrolizumab
AT takeuchisusumu acaseofinterstitiallungdiseasewithalveolarhemorrhageinducedbypembrolizumab
AT minegishiyuji acaseofinterstitiallungdiseasewithalveolarhemorrhageinducedbypembrolizumab
AT saitoyoshinobu acaseofinterstitiallungdiseasewithalveolarhemorrhageinducedbypembrolizumab
AT kubotakaoru acaseofinterstitiallungdiseasewithalveolarhemorrhageinducedbypembrolizumab
AT terasakiyasuhiro acaseofinterstitiallungdiseasewithalveolarhemorrhageinducedbypembrolizumab
AT gemmaakihiko acaseofinterstitiallungdiseasewithalveolarhemorrhageinducedbypembrolizumab
AT suganoteppei caseofinterstitiallungdiseasewithalveolarhemorrhageinducedbypembrolizumab
AT seikemasahiro caseofinterstitiallungdiseasewithalveolarhemorrhageinducedbypembrolizumab
AT nororintaro caseofinterstitiallungdiseasewithalveolarhemorrhageinducedbypembrolizumab
AT kaburakisyota caseofinterstitiallungdiseasewithalveolarhemorrhageinducedbypembrolizumab
AT tozukatakehiro caseofinterstitiallungdiseasewithalveolarhemorrhageinducedbypembrolizumab
AT takahashiakihiko caseofinterstitiallungdiseasewithalveolarhemorrhageinducedbypembrolizumab
AT takanonatsuki caseofinterstitiallungdiseasewithalveolarhemorrhageinducedbypembrolizumab
AT tanakatoru caseofinterstitiallungdiseasewithalveolarhemorrhageinducedbypembrolizumab
AT kashiwadatakeru caseofinterstitiallungdiseasewithalveolarhemorrhageinducedbypembrolizumab
AT takeuchisusumu caseofinterstitiallungdiseasewithalveolarhemorrhageinducedbypembrolizumab
AT minegishiyuji caseofinterstitiallungdiseasewithalveolarhemorrhageinducedbypembrolizumab
AT saitoyoshinobu caseofinterstitiallungdiseasewithalveolarhemorrhageinducedbypembrolizumab
AT kubotakaoru caseofinterstitiallungdiseasewithalveolarhemorrhageinducedbypembrolizumab
AT terasakiyasuhiro caseofinterstitiallungdiseasewithalveolarhemorrhageinducedbypembrolizumab
AT gemmaakihiko caseofinterstitiallungdiseasewithalveolarhemorrhageinducedbypembrolizumab